KRAZATI (adagrasib) Demonstrated Statistically Significant I

First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement in progression-free survival with KRAZATI compared to standard of care...

Related Keywords

United States , American , Bristol Myers Squibb , Tony Mok , Abderrahim Oukessou , Exchange Commission , Department Of Clinical Oncology , American Society Of Clinical Oncology , Linkedin , Mirati Therapeutics Inc , Instagram , Chinese University Of Hong Kong Cu Medicine , Twitter , Youtube , Facebook , Drug Administration , Blinded Independent Central Review , Clinical Oncology , Annual Meeting , Chinese University , Hong Kong , Bristol Myers , Myers Squibb , Mirati Therapeutics , Prescribing Information , Better Future , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports ,